Abstract
Up to 73% of patients with severe asthma have overlapping allergic and eosinophilic endophenotypes and are eligible for treatment with anti-eosinophilic (e.g., mepolizumab) or anti-IgE (omalizumab) biologics. We assessed mepolizumab real-world effectiveness in patients with severe asthma and overlapping endophenotypes based on omalizumab treatment eligibility.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.